Sign In
Buy CRSP
$48.15
+1.16 (+2.47%)
At Close: Jul 21, 2026
2 Soaring Growth Stocks That Could Rocket Even Higher
05:41am, Tuesday, 16'th May 2023
Shares of CRISPR Therapeutics and Nanox have risen sharply in 2023. CRISPR Therapeutics is developing a slate of experimental gene therapies, and the first could earn approval this year.
CRISPR Therapeutics AG (CRSP) Presents at Bank of America Securities 2023 Health Care Conference (Transcript)
07:08pm, Saturday, 13'th May 2023
CRISPR Therapeutics AG (NASDAQ:CRSP ) Bank of America Securities 2023 Health Care Conference May 9, 2023 1:40 PM ET Company Participants Sam Kulkarni - CEO Conference Call Participants Geoff Meacham -
Is CRISPR Therapeutics Stock a Buy Now?
08:45am, Saturday, 13'th May 2023
CRISPR is waiting to hear from the FDA regarding an approval for its lead therapy. The company is using gene editing to develop therapies in oncology and inherited blood disorders.
Why These 3 Nasdaq Stocks Were Glowing Green This Week
03:13pm, Thursday, 11'th May 2023
A fair number of Nasdaq-listed growth stocks moved higher this week. CRISPR Therapeutics, BioXcel Therapeutics, and Verve Therapeutics were among the biggest winners this week.
Final Trades: Berkshire, Devon Energy & CRISPR Therapeutics
02:39pm, Tuesday, 09'th May 2023
The "Halftime Report" traders give their top picks to watch for the second half.
Why CRISPR Therapeutics Stock Is on Fire Today
02:25pm, Tuesday, 09'th May 2023
CRISPR Therapeutics reported 2023 Q1 earnings yesterday. The biotech's Q1 report was full of good news for shareholders.
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Tops Revenue Estimates
07:03pm, Monday, 08'th May 2023
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $1.67. This compares to loss of $2.32 per share a year ago.
This Incredible Growth Stock Has All the Hallmarks of a Prototypical Warren Buffett Stock
01:00pm, Saturday, 06'th May 2023
Warren Buffett has a laser-like focus on owning companies with limited competition, stellar management, and sustainable profits. The rare disease specialist Vertex Pharmaceuticals ticks all of these b
3 Growth Stocks Cathie Wood Just Bought That Could Be Absolute Game-Changers
05:53am, Tuesday, 02'nd May 2023
Beam Therapeutics is a pioneer in base editing, an especially promising type of gene editing. CRISPR Therapeutics could soon bring the first CRISPR gene-editing therapy to market.
Crispr Therapeutics: Upside Likely Coming Now That Exa-Cel Is With FDA
03:00pm, Friday, 28'th Apr 2023
Two months after my last bullish note on Crispr Therapeutics, predicting a bull run, the share price has barely budged. I find this surprising. Crispr and partner Vertex have now submitted their biolo
Is It Too Late to Buy CRISPR Stock?
08:15am, Thursday, 27'th Apr 2023
CRISPR Therapeutics is on the precipice of having its first FDA-approved therapy. The upstart biotech company is also working on a range of other potential therapies.
Why CRISPR Therapeutics Just Became an Even Better Buy
10:07am, Wednesday, 26'th Apr 2023
Its gene-editing therapies could be game changers that revolutionize healthcare. If exa-cel is approved, it would serve as a functional cure for two challenging diseases.
The Best Stocks to Invest $20,000 in Right Now
02:00pm, Sunday, 23'rd Apr 2023
Investing across a few different companies could bring a lot of positive elements to your portfolio -- from dividends to growth potential. Healthcare is a great place to look for safe stocks and stock
Buy the Dip: 2 Top Stocks to Snatch Up Now
09:53am, Sunday, 23'rd Apr 2023
Sometimes stocks go on sale, and it's up to you to decide whether to bite. CRISPR Therapeutics is on the verge of what could be its first major success.
3 Stocks With Huge Catalysts on the Way
06:18am, Saturday, 22'nd Apr 2023
Axsome Therapeutics has several major milestones around the corner. CRISPR Therapeutics could soon win approvals for its first product.
